BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 16624621)

  • 41. Retroviral transduction of IL-7Ralpha into IL-7Ralpha-/- bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia.
    Jiang Q; Li WQ; Aiello FB; Klarmann KD; Keller JR; Durum SK
    Gene Ther; 2005 Dec; 12(24):1761-8. PubMed ID: 16208423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risks and benefits of gene therapy.
    Noguchi P
    N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
    [No Abstract]   [Full Text] [Related]  

  • 43. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
    Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
    J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
    Modlich U; Schambach A; Brugman MH; Wicke DC; Knoess S; Li Z; Maetzig T; Rudolph C; Schlegelberger B; Baum C
    Leukemia; 2008 Aug; 22(8):1519-28. PubMed ID: 18496560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. US panel advises resumption of gene trials.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1068-9. PubMed ID: 12410240
    [No Abstract]   [Full Text] [Related]  

  • 46. Retroviral integration site analysis in hematopoietic stem cells.
    Kustikova OS; Baum C; Fehse B
    Methods Mol Biol; 2008; 430():255-67. PubMed ID: 18370305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
    Giordano FA; Fehse B; Hotz-Wagenblatt A; Jonnakuty S; del Val C; Appelt JU; Nagy KZ; Kuehlcke K; Naundorf S; Zander AR; Zeller WJ; Ho AD; Fruehauf S; Laufs S
    Bone Marrow Transplant; 2006 Aug; 38(3):229-35. PubMed ID: 16785865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Murine hematopoietic stem cell transduction using retroviral vectors.
    Modlich U; Schambach A; Li Z; Schiedlmeier B
    Methods Mol Biol; 2009; 506():23-31. PubMed ID: 19110617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.
    Nemunaitis J; Fong T; Robbins JM; Edelman G; Edwards W; Paulson RS; Bruce J; Ognoskie N; Wynne D; Pike M; Kowal K; Merritt J; Ando D
    Cancer Gene Ther; 1999; 6(4):322-30. PubMed ID: 10419050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assays to evaluate the genotoxicity of retroviral vectors.
    Nienhuis AW
    Mol Ther; 2006 Oct; 14(4):459-60. PubMed ID: 16920033
    [No Abstract]   [Full Text] [Related]  

  • 51. Progress and prospects: gene therapy for inherited immunodeficiencies.
    Qasim W; Gaspar HB; Thrasher AJ
    Gene Ther; 2009 Nov; 16(11):1285-91. PubMed ID: 19776764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors.
    Lipnik K; Greco O; Scott S; Knapp E; Mayrhofer E; Rosenfellner D; Günzburg WH; Salmons B; Hohenadl C
    Virology; 2006 May; 349(1):121-33. PubMed ID: 16464484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
    Neschadim A; McCart JA; Keating A; Medin JA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.
    Dunbar CE
    Ann N Y Acad Sci; 2005 Jun; 1044():178-82. PubMed ID: 15958711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene therapy. Second child in French trial is found to have leukemia.
    Marshall E
    Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second cancer case halts gene-therapy trials.
    Check E
    Nature; 2003 Jan; 421(6921):305. PubMed ID: 12540867
    [No Abstract]   [Full Text] [Related]  

  • 58. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
    N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
    [No Abstract]   [Full Text] [Related]  

  • 59. Gene therapy. RAC's advice: proceed with caution.
    Kaiser J
    Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
    [No Abstract]   [Full Text] [Related]  

  • 60. Reducing the genotoxic potential of retroviral vectors.
    Ramezani A; Hawley TS; Hawley RG
    Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.